These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38133643)

  • 1. Time in Range Is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study.
    Shah VN; Kanapka LG; Akturk HK; Polsky S; Forlenza GP; Kollman C; Beck RW; Snell-Bergeon JK
    Diabetes Technol Ther; 2024 Apr; 26(4):246-251. PubMed ID: 38133643
    [No Abstract]   [Full Text] [Related]  

  • 2. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study.
    De Meulemeester J; Charleer S; Visser MM; De Block C; Mathieu C; Gillard P
    Diabetologia; 2024 Aug; 67(8):1527-1535. PubMed ID: 38787436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Diabetes Technologies and Retinopathy in Adults With Type 1 Diabetes.
    Liu TYA; Shpigel J; Khan F; Smith K; Prichett L; Channa R; Kanbour S; Jones M; Abusamaan MS; Sidhaye A; Mathioudakis N; Wolf RM
    JAMA Netw Open; 2024 Mar; 7(3):e240728. PubMed ID: 38446483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes.
    Lu J; Ma X; Zhou J; Zhang L; Mo Y; Ying L; Lu W; Zhu W; Bao Y; Vigersky RA; Jia W
    Diabetes Care; 2018 Nov; 41(11):2370-2376. PubMed ID: 30201847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy.
    Rodbard D
    Diabetes Obes Metab; 2023 Feb; 25(2):596-601. PubMed ID: 36314133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic variability assessed by continuous glucose monitoring and the risk of diabetic retinopathy in latent autoimmune diabetes of the adult and type 2 diabetes.
    Lu J; Ma X; Zhang L; Mo Y; Ying L; Lu W; Zhu W; Bao Y; Zhou J
    J Diabetes Investig; 2019 May; 10(3):753-759. PubMed ID: 30306722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of glucose time in range and area under curve in range in relation to risk of diabetic retinopathy in type 2 diabetes patients.
    Wang Y; Lu J; Shen Y; Ni J; Zhang L; Lu W; Zhu W; Bao Y; Zhou J
    J Diabetes Investig; 2022 Sep; 13(9):1543-1550. PubMed ID: 35435323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous glucose monitoring metrics following sub-Tenon's injection of triamcinolone acetonide for diabetic macular edema.
    Sotani-Ogawa R; Kusuhara S; Hirota Y; Kim KW; Matsumiya W; Ogawa W; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):449-456. PubMed ID: 37864636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes.
    Sartore G; Chilelli NC; Burlina S; Lapolla A
    Acta Diabetol; 2013 Jun; 50(3):437-42. PubMed ID: 23417155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes.
    Dunn TC; Ajjan RA; Bergenstal RM; Xu Y
    Diabetes Technol Ther; 2024 Mar; 26(3):203-210. PubMed ID: 38444315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between Daytime Versus Nighttime Continuous Glucose Monitoring Metrics with A1C in Adults with Type 1 Diabetes.
    Shah VN; Akturk HK; Vigers T; Pyle L; Oliver N; Klonoff DC
    Diabetes Technol Ther; 2023 Jan; 25(1):62-68. PubMed ID: 36306519
    [No Abstract]   [Full Text] [Related]  

  • 12. Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes.
    Yoo JH; Choi MS; Ahn J; Park SW; Kim Y; Hur KY; Jin SM; Kim G; Kim JH
    Diabetes Technol Ther; 2020 Oct; 22(10):768-776. PubMed ID: 32167394
    [No Abstract]   [Full Text] [Related]  

  • 13. A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dL.
    Beck RW; Raghinaru D; Calhoun P; Bergenstal RM
    Diabetes Technol Ther; 2024 Mar; 26(3):151-155. PubMed ID: 37870460
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.
    Keyu G; Jiaqi L; Liyin Z; Jianan Y; Li F; Zhiyi D; Qin Z; Xia L; Lin Y; Zhiguang Z
    Front Public Health; 2022; 10():990281. PubMed ID: 36091534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between HbA1c and continuous glucose monitoring metrics of glycaemic control and glucose variability in a large cohort of children and adolescents with type 1 diabetes.
    Piona C; Marigliano M; Mozzillo E; Rosanio F; Zanfardino A; Iafusco D; Maltoni G; Zucchini S; Piccinno E; Delvecchio M; Maffeis C
    Diabetes Res Clin Pract; 2021 Jul; 177():108933. PubMed ID: 34216681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving the HbA1c Target Requires Longer Time in Range in Pregnant Women With Type 1 Diabetes.
    Ling P; Yang D; Gu N; Xiao X; Lu J; Liu F; Zhou Z; Huang Q; Zhao J; Zhang M; Hu J; Luo S; Weng J; Yan J; Zheng X
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4309-e4317. PubMed ID: 34244734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The appropriate cut-off point of time in range (TIR) for evaluating glucose control in type 2 diabetes mellitus].
    Dai DJ; Lu JY; Zhang L; Shen Y; Mo YF; Lu W; Zhu W; Bao YQ; Zhou J
    Zhonghua Yi Xue Za Zhi; 2020 Oct; 100(38):2990-2996. PubMed ID: 33086449
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.
    Perais J; Agarwal R; Evans JR; Loveman E; Colquitt JL; Owens D; Hogg RE; Lawrenson JG; Takwoingi Y; Lois N
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013775. PubMed ID: 36815723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THE ADDED AND INTERPRETATIVE VALUE OF CGM-DERIVED PARAMETERS IN TYPE 1 DIABETES DEPENDS ON THE LEVEL OF GLYCEMIC CONTROL.
    Helleputte S; De Backer T; Calders P; Pauwels B; Shadid S; Lapauw B
    Endocr Pract; 2021 Jan; 27(1):44-50. PubMed ID: 33475500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a New Continuous Glucose Monitoring Metric in Children and Adolescents with Type 1 Diabetes Using Different Treatment Modalities.
    Passanisi S; Piona C; Salzano G; Marigliano M; Bombaci B; Morandi A; Alibrandi A; Maffeis C; Lombardo F
    Diabetes Technol Ther; 2024 Mar; 26(3):161-166. PubMed ID: 37902743
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.